MedPath

Iterative PICC Placement Versus Long Term Device

Phase 3
Withdrawn
Conditions
Breast Cancer
Interventions
Procedure: Iterative PICC placement
Procedure: Long term PAC placement
Registration Number
NCT02784730
Lead Sponsor
Centre Leon Berard
Brief Summary

Peripherally Inserted Central Catheter (PICC) and port-a-cath (PAC) are the most commonly medical devices used for the administration of chemotherapy.

Placement of these devices via central venous access is sometimes responsible for complications.

The incidence of these complications is correlated with the device holding time.

A strategy of iterative PICC placement could significantly reduce these complications.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria
  • Women older than 18 years old;
  • Breast cancer diagnosis histologically proven , for any histological subtypes;
  • 4 or 6 indication of neoadjuvant or adjuvant chemotherapy; according to hormonal status and HER2 of the tumors, the patient may be treated concomitantly with hormone therapy and / or trastuzumab; Nota Bene: treatment protocol adopted will imperatively be administered in 3-week cycles.
  • Central venous access indication;
  • Ability to understand and willingness to comply with the study monitoring;
  • Affiliated to the French social security system;
  • Informed Consent dated and signed, indicating that the patient has been informed of all pertinent aspects of the study before inclusion.
Exclusion Criteria
  • Any contraindication for placement of a central venous catheter ( hemostasis disorders , active infection treated with antibiotics , ...);
  • Patient who can't stop anti -vitamin K treatment ( AVK ) ( a relay by Heparin Low Molecular Weight (LMWH) is possible);
  • History of central access, regardless of the indication;
  • Any active disease other than cancer pathology , requiring repeated administration of intravenous therapy ;
  • Patient deprived of liberty;
  • Not monitoring for social, geographical, psychological or family reason.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Iterative PICC placementIterative PICC placementNew PICC placement at each chemotherapy cycle (removed after treatment administration)
Long term implantable deviceLong term PAC placementPort-a-cath inserted prio first chemotherapy cycle and maintained throughout the study
Primary Outcome Measures
NameTimeMethod
Compare complication rate for iterative placement (PICC) versus long term placement (PAC).6 months after randomization

Complication rate will be defined by the proportion of patients with at least one of the following complications from the date of randomization to the end of the study:

pneumothorax , hemothorax ,veinous thrombosis, migration or expulsion of the device, fissure or rupture of the catheter, catheter obstruction, extravasation.

Secondary Outcome Measures
NameTimeMethod
Success rate for each strategy6 months after randomization

Success rate will be determined with the proportion of patients in whom the allocation strategy was conducted until the end of the last cycle of chemotherapy

Description of failure causes for each strategy6 months after randomization

Causes of failures will be described

Quality of Life in both armsAt Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1

Quality of Life will be assessed with the EQ-5D questionnaire

Level of pain for each strategyAt Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1

Level of pain will be assessed with the verbal scale rated from 0 to 10

Trial Locations

Locations (1)

Julien GAUTIER

🇫🇷

Lyon, France

© Copyright 2025. All Rights Reserved by MedPath